Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial

References

• SabnisGJMacedoLFGoloubevaOSchayowitzABrodieAMStopping treatment can reverse acquired resistance to letrozoleCancer Res200868124518452418559495
   PubMed Web of Science ®Google Scholar
• TangLCYinWJDiGHShenZZShaoZMUnfavourable clinicopathologic features and low response rate to systemic adjuvant therapy: results with regard to poor survival in young Chinese breast cancer patientsBreast Cancer Res Treat201012219510419760032
   PubMed Web of Science ®Google Scholar
• CoombesRCHallEGibsonLJA randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerN Engl J Med2004350111081109215014181
   PubMed Web of Science ®Google Scholar
• JakeszRJonatWGnantMSwitching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialLancet2005366948445546216084253
   PubMed Web of Science ®Google Scholar
• Tamoxifen for early breast cancer: an overview of the randomised trialsEarly Breast Cancer Trialists’ Collaborative GroupLancet19983519114145114679605801
   PubMed Web of Science ®Google Scholar
• BaumMHackshawAHoughtonJAdjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP studyEur J Cancer200642789590416545560
   PubMed Web of Science ®Google Scholar
• Castiglione-GertschMO’NeillAPriceKNAdjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trialJ Natl Cancer Inst2003951833184614679153
   PubMedGoogle Scholar
• KarlssonPSunZBraunDLong-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancerAnn Oncol201122102216222621325445
   PubMed Web of Science ®Google Scholar
• CarlsonRWTheriaultRSchurmanCMPhase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal womenJ Clin Oncol201028253917392120679610
   PubMed Web of Science ®Google Scholar
• TorrisiRBagnardiVRotmenszNLetrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancerBreast Cancer Res Treat2011126243144121221766
   PubMed Web of Science ®Google Scholar
• MasudaNSagaraYKinoshitaTNeoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised Phase 3 trialLancet Oncol201213434535222265697
   PubMed Web of Science ®Google Scholar
• JannuzzoMGdi SalleESpinelliRPirottaNBuchanPBelloAEstrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin aloneBreast Cancer Res Treat2009113349149918330698
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBStoegerHAdjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trialLancet Oncol201112763164121641868
   PubMed Web of Science ®Google Scholar
• PaganiOReganMMWalleyBAAdjuvant exemestane with ovarian suppression in premenopausal breast cancerN Engl J Med2014371210711824881463
   PubMed Web of Science ®Google Scholar
• Prevention and management of osteoporosisWorld Health Organ Tech Rep Ser2003921116415293701
   PubMed Web of Science ®Google Scholar
• BradyMJCellaDFMoFReliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrumentJ Clin Oncol19971539749869060536
   PubMed Web of Science ®Google Scholar
• MazerNALeiblumSRRosenRCThe brief index of sexual functioning for women (BISF-W): a new scoring algorithm and comparison of normative and surgically menopausal populationsMenopause20007535036310993034
   PubMed Web of Science ®Google Scholar
• FrancisPAPaganiOFlemingGFTailoring adjuvant endocrine therapy for premenopausal breast cancerN Engl J Med2018379212213729863451
   PubMed Web of Science ®Google Scholar
• BernhardJZahriehDCastiglione-GertschMAdjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients – the International Breast Cancer Study Group Trial VIIIJ Clin Oncol200725326327017159194
   PubMed Web of Science ®Google Scholar
• ForbesJFCuzickJBuzdarAEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialLancet Oncol20089455318083636
   PubMed Web of Science ®Google Scholar
• KlijnJGBeexLVMauriacLCombined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized studyJ Natl Cancer Inst2000921190391110841825
   PubMedGoogle Scholar
• PowlesTJHickishTKanisJATidyAAshleySEffect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal womenJ Clin Oncol199614178848558225
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBLuschin-EbengreuthGAdjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudyLancet Oncol20089984084918718815
   PubMed Web of Science ®Google Scholar
• GnantMFMlineritschBLuschin-EbengreuthGZoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study GroupJ Clin Oncol200725782082817159195
   PubMed Web of Science ®Google Scholar